Fatal Hepatitis Associated with Nivolumab and Ipilimumab Combination Therapy in the Patient with Malignant Melanoma

Authors: Umefune R, Kato Y*, Kanda Y, Kimura Y, Shimai Y, Nakamura H and Umebayashi Y

DOI: 10.23880/cdoaj-16000262

Volume 7, Issue 1

Abstract

Immune checkpoint inhibitors are a common treatment for various malignancies, but these therapies are associated with several, immune-related adverse events. We report herein a case of fatal hepatitis caused by nivolumab and ipilimumab combination therapy in the patient of malignant melanoma. Physicians should be aware of the possibility of potentially fatal liver injury resulting from immune checkpoint inhibitors treatment and initiate countermeasures as soon as signs of liver injury become apparent.

Keywords: Immune-related adverse event, Malignant melanoma, Combination therapy, Fatal hepatitis

View PDF